Cost analysis of type 2 diabetes mellitus treatment in economically developed countries

Sara Ramzan, Peter Timmins, Syed Shahzad Hasan, Zaheer-Ud-Din Babar

Research output: Contribution to journalReview article

Abstract

INTRODUCTION: There is a growing need to evaluate the factors contributing to the increase in health expenditures, as well as the cost of medicines used in the treatment of Type 2 diabetes mellitus (T2DM) in the economically developed countries. Areas covered: A systematic searching of studies describing the direct cost of T2DM and medicine cost of treating T2DM. The quality of the studies found eligible for this study were assessed using a methodological quality appraisal tool. Nine studies were included in this review. All the included studies had data on direct cost and antidiabetic medicine cost of health care. Mean annual direct cost per person/year ranged between US$220 and US$7600. The two components with the greatest impact on direct cost were found to be medicines and hospitalization. The mean annual medicines cost per person/year was found to range between US$140 and US$2990. Expert commentary: There is an increased expenditure on treatment of T2DM. However, it is still not clear how the increased use of antidiabetic medicines is reflected in the overall expenditures. Further, we suggest a more comprehensive understanding of prescription patterns as older drugs are more expensive than the newer drugs, hence they are still under patent.

LanguageEnglish
Pages5-14
Number of pages10
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume19
Issue number1
Early online date4 Sep 2018
DOIs
Publication statusPublished - 2 Jan 2019

Fingerprint

Developed Countries
Type 2 Diabetes Mellitus
Costs and Cost Analysis
Health Expenditures
Hypoglycemic Agents
Therapeutics
Medicine
Pharmaceutical Preparations
Health Care Costs
Prescriptions
Hospitalization

Cite this

@article{00e29e29c70b4caba7b5e14a60fa2600,
title = "Cost analysis of type 2 diabetes mellitus treatment in economically developed countries",
abstract = "INTRODUCTION: There is a growing need to evaluate the factors contributing to the increase in health expenditures, as well as the cost of medicines used in the treatment of Type 2 diabetes mellitus (T2DM) in the economically developed countries. Areas covered: A systematic searching of studies describing the direct cost of T2DM and medicine cost of treating T2DM. The quality of the studies found eligible for this study were assessed using a methodological quality appraisal tool. Nine studies were included in this review. All the included studies had data on direct cost and antidiabetic medicine cost of health care. Mean annual direct cost per person/year ranged between US$220 and US$7600. The two components with the greatest impact on direct cost were found to be medicines and hospitalization. The mean annual medicines cost per person/year was found to range between US$140 and US$2990. Expert commentary: There is an increased expenditure on treatment of T2DM. However, it is still not clear how the increased use of antidiabetic medicines is reflected in the overall expenditures. Further, we suggest a more comprehensive understanding of prescription patterns as older drugs are more expensive than the newer drugs, hence they are still under patent.",
keywords = "Type 2 diabetes mellitus, type 2 diabetes, economics, health care costs, drugs, health expenditure, medicines, chronic disease, cost",
author = "Sara Ramzan and Peter Timmins and Hasan, {Syed Shahzad} and Zaheer-Ud-Din Babar",
year = "2019",
month = "1",
day = "2",
doi = "10.1080/14737167.2018.1513790",
language = "English",
volume = "19",
pages = "5--14",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "1",

}

Cost analysis of type 2 diabetes mellitus treatment in economically developed countries. / Ramzan, Sara; Timmins, Peter; Hasan, Syed Shahzad; Babar, Zaheer-Ud-Din.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 19, No. 1, 02.01.2019, p. 5-14.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cost analysis of type 2 diabetes mellitus treatment in economically developed countries

AU - Ramzan, Sara

AU - Timmins, Peter

AU - Hasan, Syed Shahzad

AU - Babar, Zaheer-Ud-Din

PY - 2019/1/2

Y1 - 2019/1/2

N2 - INTRODUCTION: There is a growing need to evaluate the factors contributing to the increase in health expenditures, as well as the cost of medicines used in the treatment of Type 2 diabetes mellitus (T2DM) in the economically developed countries. Areas covered: A systematic searching of studies describing the direct cost of T2DM and medicine cost of treating T2DM. The quality of the studies found eligible for this study were assessed using a methodological quality appraisal tool. Nine studies were included in this review. All the included studies had data on direct cost and antidiabetic medicine cost of health care. Mean annual direct cost per person/year ranged between US$220 and US$7600. The two components with the greatest impact on direct cost were found to be medicines and hospitalization. The mean annual medicines cost per person/year was found to range between US$140 and US$2990. Expert commentary: There is an increased expenditure on treatment of T2DM. However, it is still not clear how the increased use of antidiabetic medicines is reflected in the overall expenditures. Further, we suggest a more comprehensive understanding of prescription patterns as older drugs are more expensive than the newer drugs, hence they are still under patent.

AB - INTRODUCTION: There is a growing need to evaluate the factors contributing to the increase in health expenditures, as well as the cost of medicines used in the treatment of Type 2 diabetes mellitus (T2DM) in the economically developed countries. Areas covered: A systematic searching of studies describing the direct cost of T2DM and medicine cost of treating T2DM. The quality of the studies found eligible for this study were assessed using a methodological quality appraisal tool. Nine studies were included in this review. All the included studies had data on direct cost and antidiabetic medicine cost of health care. Mean annual direct cost per person/year ranged between US$220 and US$7600. The two components with the greatest impact on direct cost were found to be medicines and hospitalization. The mean annual medicines cost per person/year was found to range between US$140 and US$2990. Expert commentary: There is an increased expenditure on treatment of T2DM. However, it is still not clear how the increased use of antidiabetic medicines is reflected in the overall expenditures. Further, we suggest a more comprehensive understanding of prescription patterns as older drugs are more expensive than the newer drugs, hence they are still under patent.

KW - Type 2 diabetes mellitus

KW - type 2 diabetes

KW - economics

KW - health care costs

KW - drugs

KW - health expenditure

KW - medicines

KW - chronic disease

KW - cost

UR - http://www.scopus.com/inward/record.url?scp=85058799193&partnerID=8YFLogxK

U2 - 10.1080/14737167.2018.1513790

DO - 10.1080/14737167.2018.1513790

M3 - Review article

VL - 19

SP - 5

EP - 14

JO - Expert Review of Pharmacoeconomics and Outcomes Research

T2 - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 1

ER -